TrialSignal
Clinical trial intelligence report
A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01280526
Status
COMPLETED
Phase
PHASE1
Sponsor
The Lymphoma Academic Research Organisation
Executive brief
Investment-Ready Snapshot
This study is an open label, multicenter study with two phases: * A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell lymphoma. * An expansion phase in order to assess the safety and the efficacy of the association of the recommended dose of Romidepsin associated with CHOP in a population of patients with T-cell lymphoma.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01280526
Indication
Peripheral T Cell Lymphoma
Modality
small molecule
Target
Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP
Intervention
Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP, Romidepsin and CHOP
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.